Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

518results about How to "Increase synthesis" patented technology

Non-stochastic generation of genetic vaccines

InactiveUS6479258B1Improve abilitiesPotent and direct effect on proliferation and Ig-synthesisHydrolasesLibrary screeningAntigenMutagenic Process
This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-satuaration mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.
Owner:VERENIUM CORPORATION

Steam methane reforming method

A steam methane reforming method in which a feed stream is treated in a reactor containing a catalyst that is capable of promoting both hydrogenation and partial oxidation reactions. The reactor is either operated in a catalytic hydrogenation mode to convert olefins into saturated hydrocarbons and / or to chemically reduce sulfur species to hydrogen sulfide or a catalytic oxidative mode utilizing oxygen and steam to prereform the feed and thus, increase the hydrogen content of a synthesis gas produced by a steam methane reformer. The method is applicable to the treatment of feed streams containing at least 15% by volume of hydrocarbons with two or more carbon atoms and / or 3% by volume of olefins, such as a refinery off-gas. In such case, the catalytic oxidative mode is conducted with a steam to carbon ratio of less than 0.5, an oxygen to carbon ratio of less than 0.25 and a reaction temperature of between about 500° C. and about 860° C. to limit the feed to the steam methane reformer to volumetric dry concentrations of less than about 0.5% for the olefins and less than about 10% for alkanes with two or more carbon atoms.
Owner:PRAXAIR TECH INC

Method of treating vulnerable plaque

InactiveUS6972024B1Minimizing avoiding damageIncrease synthesisStentsEar treatmentSelf limitingVulnerable plaque
A method of treating vulnerable plaque comprising intentionally damaging or rupturing the vulnerable plaque using a wingless balloon which is inflated from a wingless unexpanded diameter to a limited expanded diameter. This process produces significant increase in ECM synthesis at the site of the damage or rupture. As a result, the method strengthens the vulnerable plaque while minimizing or avoiding damage to the surrounding wall of the body lumen or damaging a stable plaque mistakenly believed to be a vulnerable plaque. The method of the invention is particularly useful in treating a fibroatheroma type of vulnerable plaque. In one embodiment, the balloon is self-limiting such that it expands compliantly at initial inflation pressures, and above nominal pressure it expands noncompliantly. In an alternative embodiment, the balloon is inflated using a diameter-limiting device, such as a device which limits the inflation pressure or the volume of inflation fluid in the balloon.
Owner:ABBOTT CARDIOVASCULAR

Non-stochastic generation of genetic vaccines and enzymes

InactiveUS6713279B1Improve abilitiesPotent and direct effect on proliferation and Ig-synthesisAnimal cellsHydrolasesAntigenBiological property
This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical & / or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.
Owner:BP CORP NORTH AMERICA INC

Video coding system using texture analysis and synthesis in a scalable coding framework

An apparatus or method of efficiently coding high resolution video using texture analysis and synthesis techniques in a scalable video coding framework. A high-resolution video signal is spatially downsampled and encoded into a base-layer. Texture and structure information are extracted from the downsampled signal and base-layer for use by a texture synthesizer. The texture synthesizer is structurally and texturally aware utilizing edge information from a base-layer of the synthesizer to improve synthesis. After synthesis, a video quality assessor directs enhancement-layer coding of unacceptably synthesized areas by alternate (non-textural) coding means, such as conventional AVC or MPEG-2 coding. In one mode, the quality assessor iteratively improves synthesis of certain blocks to make them acceptable for enhancement-layer coding. The apparatus or method outputs a bit stream, or bit streams, containing both the coded base-layer and the enhancement-layer.
Owner:SONY CORP +1

Plant Genes Associated With Seed Oil Content And Methods Of Their Use

Cytochrome b5 (Cb5) is a haem-binding protein located in the endoplasmic reticulum (ER) and the outer mitochondrial membranes of higher eukaryotes. In higher plants, animals, and fungi, the ER resident Cb5 has been shown to play a role in desaturation of acyl CoA fatty acids. Higher plants Cb5 isoforms from plants such as soybean or Arabidopsis are capable of modulating omega-3 desaturation. Co-expression of certain Cb5 isoforms with FAD3 in a host plant results in increased production of seed oil content as well as altered ratio between different fatty acids. It is also disclosed here that overexpression of Yarrowia ACL enzymes in the plastids of a host plant helps boost the synthesis of acetyl CoA, which in turn, may lead to increased synthesis of fatty acids and enhanced oil accumulation in the seeds.
Owner:UNIVERSITY OF MISSOURI

Kits and methods for generating 5' capped RNA

The present invention relates to kits and methods for efficiently generating 5′ capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. The invention is used to obtain novel compositions of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5′-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA for a variety of research, therapeutic, and commercial applications. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5′-diphosphate, such as RNA synthesized in vitro or obtained from a biological source, including prokaryotic mRNA that is in a mixture with other prokaryotic and / or eukaryotic nucleic acids. The method for capturing modified-nucleotide-capped RNA also provides methods and kits for obtaining only type-specific or condition-specific modified-nucleotide-capped RNA by cap-dependent subtraction of that portion of the captured modified-nucleotide-capped RNA in cells of one type or condition that is the same as RNA in cells of another type or condition. The invention further provides methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5′-diphosphate with detectable dye or enzyme moieties.
Owner:CELLSCRIPT

Apparatus and method for ultrasonically and electromagnetically treating tissue

The invention relates to apparatus and method for ultrasonically and electromagnetically treating tissue to treat, for example, traumatized tissue or a bone injury. The apparatus includes at least one ultrasonic transducer assembly and at least one electromagnetic coil-assembly configured to cooperate with a placement module for placement in proximity to the treatment area. The apparatus also utilizes a portable main operating unit constructed to fit within a pouch or carrying case worn by the patient. In operation, at least one ultrasonic transducer and at least one electromagnetic coil are activated by transmitting control signals to the placement module from the main operating unit. The activation of the at least one ultrasonic transducer causes ultrasonic waves to be propagated toward the treatment area which are modulated by electrostatic and magnetic forces generated by the at least one electromagnetic coil. The activation of the at least one ultrasonic transducer and the at least one electromagnetic coil may be performed at the same time or at different times for varying periods.
Owner:EXOGEN

Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup
Owner:PFIZER INC

Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions

InactiveUS20080108681A1Improving appearance and texture and firmnessIncrease synthesisCosmetic preparationsOrganic active ingredientsFine lineWrinkle skin
Compositions comprising allantoin and an acceptable carrier and methods of using such compositions to increase pro-collagen synthesis in skin are disclosed. Compositions of the present invention may be used to decrease the signs of skin aging such as wrinkles and fine lines. Compositions of the present invention may be topically administered, orally administered or parenterally, such as administration by injection. When topically administered, additive ingredients such as penetration enhancers, fragrances, and moisturizers and cosmetic adjuvants may be included in compositions of the present invention.
Owner:ACCESS BUSINESS GRP INT LLC

Bio-organic compound fertilizer

The invention relates to a bio-organic compound fertilizer, which comprises the following components in part by weight: 10 to 30 parts of organic matter, 2 to 10 parts of compound microbial inoculants, 5 to 20 parts of humic acid, 5 to 20 parts of amino acid, 4 to 10 parts of chitin, 1 to 5 parts of polypeptide, 530 parts of nitrogen, phosphorus and potassium, 5 to 10 parts of secondary and trace elements, 5 to 15 parts of algae fertilizer, 5 to 10 parts of zeolite powder and 1 to 5 parts of synergistic agent. Through the scientific and rational formula, the bio-organic compound fertilizer achieves nutritive equilibrium and can satisfy the need of crop growth in nutrient. The microbial inoculants are added to quickly degrade natural macromolecular organic compounds into the organic fertilizer and decompose organic pollutants, which effectively improves the capacity of crops in the absorption of nutrient components, reduces the waste of the fertilizer and reduces the damage of the chemical fertilizer to soil to further achieve the nutritive equilibrium, satisfy the need of the crop growth in the nutrient, achieve the aims of low investment and high output value, improve the quality of the crops and improve the economic benefit brought by the crops.
Owner:张钧

Magnolia extract containing compositions

Disclosed is a composition comprising at least two of the following ingredients: Magnolia extract, honokiol, humulus lupulus extract, hesperidin methyl chalcone, gotu kola, dipeptide valyl-tryptophane, palmitoyl tetrapeptide-3, corylus avellana bud extract, centella asiatica extract, cucumis sativa extract, morus alba extract, hibiscus sabdariffa flower extract, vitis vinifera extract, ascorbyl glucoside, citrus medica limonum extract, avena sativa kernel extract, hydrolyzed soy protein, aniseed myrtle extract, tasmania lanceolata leaf extract, artemisia abrotanum extract, or citrus grandis fruit extract or any combination thereof. Also disclosed are methods of treating skin conditions by topically applying the composition to skin.
Owner:MARY KAY INC

Compositions for enhancing DNA synthesis, DNA polymerase-related factors and utilization thereof

The invention provides methods, kits, and compositions for enhancing synthesis of DNA involving a carboxylate ion-supplying substance that is effective in promoting DNA synthesis in enzymatic DNA synthesis reactions. The invention further provides a thermostable DNA polymerase-related factor derived from Thermococcus species, which has an activity to promote the DNA synthesis activity of DNA polymerase or which binds to DNA polymerase.
Owner:TOYOBO CO LTD

Method of de-differentiating and re-differentiating somatic cells using RNA

RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.
Owner:YALE UNIV

In vitro synthesis of polypeptides by optimizing amino acid metabolism

InactiveUS6994986B2Increasing protein synthesisDecrease and eliminate enzyme activityBacteriaTumor necrosis factorHigh-energy phosphateHomeostatic system
Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides. In order to improve the performance of in vitro protein synthesis reactions, metabolic inhibitors, or manipulation of a source organism, is used to diminish or avoid the action of enzymes responsible for undesirable amino acids production or depletion. A homeostatic system may be used for production of ATP, where the required high energy phosphate bonds are generated in situ, e.g. through coupling with an oxidation reaction. The homeostatic energy source will typically lack high energy phosphate bonds itself, and will therefore utilize free phosphate in the reaction mix during generation of ATP. The homeostatic energy source is provided in combination with an enzyme that catalyzes the creation of high energy phosphate bonds and with an enzyme that can use that high energy phosphate bond to regenerate ATP.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor

Methods are disclosed for correcting biological information transfer in a patient in need of such therapy which comprise administration to a patient of a composition comprising a therapeutically effective amount of a biocomplex comprising at least one bioactive agent from each of the three informational blocks of biological information transfer, each agent being present in an amount sufficient to correct the biological information transfer of the patient under treatment and resulting in the resumption of normal cell metabolism, said amount being less than the buffering amount of said agent; together with a carrier therefor.
Owner:DANIELOV MICHAEL M

Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses

ActiveUS20080113411A1Increased and decreased binding strengthStability propertyPeptide/protein ingredientsAntibody mimetics/scaffoldsChemistryBlood plasma
Modified human plasma polypeptides or Fc and uses thereof are provided.
Owner:AMBRX

Compositions comprising kakadu plum extract or acai berry extract

InactiveUS20070166275A1Increase stratum corneum turnover rateIncrease collagen synthesisCosmetic preparationsBiocideMedicineAcai Berries
A topical skin care composition comprising kakadu plum extract or acai berry extract, or a combination of both, is disclosed. The composition can include a high oxygen radical absorbance capacity (ORAC) value. The composition can improve the skin's visual appearance, physiological functions, clinical properties, and / or biophysical properties.
Owner:MARY KAY INC

Dialog processing method and apparatus for uninhabited air vehicles

A dialog processing method and apparatus for uninhabited air vehicles is described. The apparatus contains a recognition unit for recognizing incoming data, an interpretation unit for interpreting the data according to a grammar and a response unit for generating an appropriate response to the incoming data. The method may utilize natural language processes and may reduce to a finite state machine. The incoming data is combined with uninhabited air vehicle state information to increase the accuracy of this interpretation. Additionally, the dialog states may be limited to customary air traffic control dialogs.
Owner:LOCKHEED MARTIN CORP

Methods and compositions for modulating hair growth or regrowth

The present invention relates to compositions and methods for modulating hair growth or regrowth. The compositions of the present invention comprise extracts of one or more of the following: Boswellia serrata, Undaria pinnatifida, green tea (e.g., Camellia sinensis), shiso, Pureraria mirifica, luteolin (e.g. Perilla ocymoides leaf extract), astilbin, vitamin E, amentoflavone, tetrahydropiperine, licochalcone, astaxanthin, red clover, Brassica juncea, unfermented green rooibos, enzyme CoQ10, salvia, ximenynic acid, hops oleoresin, apple, soy, saw palmetto, or ellagic extract, or any derivative thereof. In particular, the compositions and methods of the present invention can be used to stimulate or increase hair growth and / or prevent or slow the loss of hair by having one or more of the following functions: (a) inhibiting synthesis of DHT; (b) inhibiting proteasomal activity; (c) inhibiting IL-1 activity; (d) increasing vascularization; (e) increasing expression of vascular endothelial growth factor; (f) increasing expression of keratinocyte growth factor; (g) inhibiting inflammation; or (h) acting as an antibacterial.
Owner:ACCESS BUSINESS GRP INT LLC

Topical skin care formulations

Disclosed is a topical skin care composition that includes water, silymarin, hydrolyzed algin, palmitoyl tripeptide 8, ceramide 2, pomegranate extract comprising pomegranate sterols, glycerin, disodium EDTA, caprylic / capric triglyceride, shea butter, C12-15 alcohols benzoate, dimethicone, glyceryl stearate and PEG 100 stearate, cetyl alcohol, stearyl alcohol, stearic acid, butylene glycol, caprylyl glycol, and (s) a mixture of acrylamide / sodium acryloyldimethyl taurate copolymer, isohexadecane, and polysorbate 80.
Owner:MARY KAY INC

Compositions and methods for glycogen synthesis

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and / or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and / or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.
Owner:TSI INC

Increasing levels of nicotinic alkaloids in plants

Four genes, A622, NBB1, PMT, and QPT, can be influenced for increasing nicotinic alkaloid levels in Nicotiana plants, as well as for synthesizing nicotinic alkaloids in non-nicotine producing plants and cells. In particular, overexpressing one or more of A622, NBB1, PMT, and QPT may be used to increase nicotine and nicotinic alkaloid levels in tobacco plants. Non-nicotine producing cells can be engineered to produce nicotine and related compounds by overexpressing A622 and
Owner:22ND CENTURY LTD LLC

Compositions for Preventing and Reducing Delayed Onset Muscle Soreness

The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and / or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of mental tranquility immediately following exercise. The composition consists of any or all high-glycemic sugars and / or polysaccharides (e.g., sucrose, glucose, maltodextrin), all essential amino acids and beta-hydroxy-beta-methylbutyrate and can include other amino acids sources (e.g. whey protein), performance enhancing agents (e.g., caffeine, L-glutamate), anti-inflammatory agents (e.g., ginger, boswellia, curcumen), antioxidants (vitamin C, vitamin E, selenium, polyphenols,), insulin-mimicking agents (cinnamon, Banaba), analgesics (e.g. aspirin, ibuprofen, naproxen, acetaminophen), and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.
Owner:SOUTHWEST IMMUNOLOGY

Sustained release of apo a-i mimetic peptides and methods of treatment

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.
Owner:ABBOTT CARDIOVASCULAR

Generating synthetic data

Methods for generating synthetic data based on time dependent data with increased accuracy include decomposing a base dataset into a base dynamic component and at least one static component. Decomposing the base dataset includes applying a decomposition model to the base dataset. One or more embodiments generate a synthetic dynamic component based on the base dynamic component. One or more embodiments merge the synthetic dynamic component with the at least one static component to generate a synthetic dataset having at least some of the time dependent characteristics of the base dataset.
Owner:ADOBE SYST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products